Omega Pacific Closes First Tranche of Non-Brokered Private Placement
Omega Pacific Clarifies Size of Previously Announced Private Placement
Omega Pacific Announces Non-Brokered Private Placement
Omega Pacific Acquires 100% of Williams Property
Omega Pacific Closes Non-Brokered Private Placement
Omega Pacific Closes First Tranche of Offering
Omega Pacific Announces Private Placement
Omega Pacific Outlines 2025 Exploration Program in the Revitalized Toodoggone District
Omega Pacific Reports Its Final Drill Hole Yielding Multiple Zones of Mineralization at Its Williams Property
Omega Pacific Announces 2024 Work Program Results From Its Lekcin Property
Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates
Omega Pacific Earns 51% Interest in Williams Property
Omega Pacific Adds John Williamson as Independent Director
Omega Pacific Extends Historical Hole WM22-02 Mineralization to 2.16 G/t Au Over 96.92 Metres
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
Omega Pacific Issues Common Shares for Three Additional Claims in the Golden Horseshoe Area in British Columbia
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
Omega Pacific Intersects Three Separate Gold Zones Demonstrating Bulk-Tonnage Gold Mineralization at its Williams Property
Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates
Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Omega Pacific Provides Project Overview for its Williams Property
Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
Omega Therapeutics To Participate In Two Upcoming Investor Conferences
Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
Omega Therapeutics (OMGA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
Omega Therapeutics (OMGA) Upgraded to Buy: Here's What You Should Know
Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'
Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
Omega Therapeutics: The Next Weight Loss Drug Runner
The 3 Best Biotech Stocks to Buy in January 2024
Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk
Why Is Omega Therapeutics (OMGA) Stock Up 111% Today?
Omega Therapeutics shares surge on obesity collaboration with Novo Nordisk
Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference
Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis
Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Omega Therapeutics to Participate in The Jefferies London Healthcare Conference
Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller
Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC